NASDAQ:SYRE News 2 January 2026 - 5 January 2026

New York, January 5, 2026, 15:09 EST — Regular session Shares of Spyre Therapeutics Inc fell 2.7% to $29.75 in afternoon trading on Monday, extending a choppy start to the year for smaller biotechnology names. The stock traded between $28.02 and $30.75, with about 0.63 million shares changing hands. The decline tracked weakness across the biotech complex, with the SPDR S&P Biotech ETF down 1.7% and the iShares Nasdaq Biotechnology ETF off 1.5%. Both are exchange-traded funds, meaning baskets of stocks that trade like a single share, while the SPDR S&P 500 ETF rose 0.7%, underscoring the sector’s underperformance. That

NEW YORK, Jan 4, 2026, 11:15 ET — Market closed Spyre Therapeutics shares fell 6.6% to $30.58 on Friday, then ticked up about 2% in after-hours trading, as U.S. markets headed into the weekend. Yahoo Finance With markets shut on Sunday, the Friday move leaves Spyre starting the new week with momentum tilted lower — a reminder that development-stage biotech stocks can swing sharply even without fresh headlines. That matters now because Spyre’s valuation hinges on clinical data due in 2026, not product sales. Any shift in expectations for timing or quality of those readouts can drive outsized moves. In